Get the Stockscreener App
61.07
1.08%
0.65
Pre-market:
61.16
0.09
+0.15%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co Stock (BMY) Latest News
Is Bristol-Myers Squibb (BMY) Among the Cheap Stocks to Buy According to Billionaires? - Insider Monkey
Bristol-Myers Squibb Company (BMY): Among Incredibly Cheap Dividend Stock to Buy Now - Insider Monkey
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed - Benzinga
Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy (NYSE:MRK) - Seeking Alpha
Layoff Tracker: Vaxart Cuts 10% of Staff After US Government Orders Vaccine Trial Halt - BioSpace
Is Bristol-Myers Squibb Company (BMY) The Best Undervalued Stock to Buy According to Billionaires? - Insider Monkey
Bristol Myers Squibb Names GM for Saudi Arabia and Gulf Countries - Contract Pharma
Bristol Myers Squibb Appoints Osama Braiwish as General Manager for Saudi Arabia & Gulf Countries - The Malaysian Reserve
Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note - Yahoo Finance
Is Bristol-Myers Squibb (BMY) the Most Undervalued Biotech Stock to Invest In? - Insider Monkey
Bristol-Myers Squibb: Why I'm Still Bullish (NYSE:BMY) - Seeking Alpha
7 Most Undervalued Biotech Stocks To Invest In - Insider Monkey
Bristol-Myers Squibb Company (BMY): A Bull Case Theory - Yahoo Finance UK
EC approves Bristol Myers Squibb’s follicular lymphoma CAR T therapy - Yahoo Finance
About us - Bristol Myers Squibb
StockWatch: Will BMS–2seventy Deal Prove a Win-Win? - Genetic Engineering & Biotechnology News
Why Bristol-Myers Squibb Company (BMY) Went Down On Thursday? - Insider Monkey
Why Bristol-Myers Squibb Company (BMY) Went Down On Friday? - Yahoo Finance
Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer - Benzinga
Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment - Yahoo Finance
European Commission expands approval for Bristol Myers Squibb’s lymphoma therapy By Investing.com - Investing.com South Africa
European Commission expands approval for Bristol Myers Squibb’s lymphoma therapy - Investing.com
Bristol Myers Squibb’s Breyanzi gets EU nod for lymphoma treatment - Investing.com
Bristol Myers Squibb Receives Approval From The European Commission To Expand Use Of Car T Cell Therapy Breyanzi For Relapsed Or Refractory Follicular Lymphoma - Marketscreener.com
Bristol Myers Squibb to acquire 2seventy bio for USD 286 million - Medical Dialogues
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst - Benzinga
Bristol Meyers Squibb to Acquire 2seventy bio - Contract Pharma
Bristol Myers Squibb Sets Critical Q1 Earnings Date: What Investors Should Mark on Their Calendar - StockTitan
William Blair Issues Optimistic Estimate for BMY Earnings - Defense World
Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy According to Hedge Funds? - Insider Monkey
Bristol-Myers Squibb at Leerink Global Healthcare Conference: Pipeline Progress and Strategic Insights - Investing.com India
BMS $286m partner buy secures Abecma and closes chapter on bluebird - BioXconomy
Melanoma Therapeutics Market to Reach $ 8.35 Bn by 2032Key - openPR
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know - Yahoo Finance
11 Best Pharma Stocks to Buy According to Hedge Funds - Insider Monkey
BMS to acquire longtime cell therapy partner 2seventy bio for $286m - Pharmaceutical Technology
Bristol Myers Squibb (BMY) Shares Cross 4% Yield Mark - Nasdaq
Bristol Myers Squibb Acquires 2seventy bio for $286 Million - Lawyer Monthly Magazine
Bristol-Myers Squibb Company agreed to acquire 2seventy bio, Inc. for approximately $280 million. - Marketscreener.com
Bristol-Myers Squibb Company agreed to acquire 2seventy bio, Inc.. -March 10, 2025 - Marketscreener.com
Eaton's Bold Acquisition Moves Into Data Centers - Finimize
2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M - BioPharma Dive
Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million - Reuters
In buying cell therapy partner 2seventy bio for $286M, BMS takes full control of Abecma - FiercePharma
Bristol Myers to acquire cell therapy partner 2seventy bio in $286M all-cash deal - MSN
Bristol Myers Squibb's Bold Move: Acquiring 2seventy Bio - Finimize
BMS Buys Abecma Partner 2seventy for $286M, Ending Cost Sharing Agreement - BioSpace
Bristol Myers to acquire cell therapy partner 2seventy bio in $286M all-cash deal (BMY:NYSE) - Seeking Alpha
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - BioSpace
Bristol Myers to acquire 2seventy bio for $286 million - Investing.com India
1.14%
1.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):